Aspira Women's Health Enters Lab Services Agreement with Mayo Clinic

What Happened

• Aspira Women's Health Inc. (AWHL) filed an 8‑K on March 25, 2026 disclosing that it entered into a Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories, effective December 16, 2025. Aspira initially disclosed the arrangement on December 23, 2025 but delayed filing the agreement while finalizing redactions of private/confidential information. The agreement is included as Exhibit 10.1 to the 8‑K.

Key Details

• Parties: Aspira Women's Health Inc. and Mayo Collaborative Services, Inc. (Mayo Clinic Laboratories).
• Effective date of the agreement: December 16, 2025; public disclosure first made Dec 23, 2025.
• Filing date of 8‑K with the agreement (Exhibit 10.1): March 25, 2026; signed by CFO Brian Hungerford.
• Reason for delayed filing: finalizing appropriate redactions of confidential information.

Why It Matters

• This is a material definitive agreement related to laboratory services, which could affect Aspira’s testing operations, service delivery, and related revenue or cost structures going forward.
• Investors should note the formalization of a relationship with a major reference lab (Mayo Clinic Laboratories), and watch for future disclosures that describe the commercial terms, scope of services, and any financial impact.